Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP8942)
Name
Calycosin
Synonyms
Calycosin; 20575-57-9; 3'-hydroxyformononetin; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one; UNII-09N3E8P7TA; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 3',7-dihydroxy-4'-methoxyisoflavone; 09N3E8P7TA; CHEBI:17793; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 7,3'-dihydroxy-4'-methoxyisoflavone; HSDB 8109; 3-Hydroxyformononetin; 3'-hydroxy-formononetin; SCHEMBL73013; MLS000876988; CHEMBL241608; MEGxp0_001325; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromen-4-one; ACon1_000650; DTXSID70174580; HMS2268B05; BCP28682; HY-N0519; ZINC6018563; LMPK12050056; MFCD00210598; s9038; AKOS015896719; 3',7-dihydroxy-4'-methoxy-isoflavone; AC-8043; CS-3715; MCULE-7559555984; NCGC00169494-01; AK168211; LS-14468; SMR000440659; DB-045290; FT-0630465; N1412; X1103; C01562; 575C579; A814711; Q-100254; Q5024637; BRD-K05039497-001-01-6; 3-(4-methoxy-3-oxidanyl-phenyl)-7-oxidanyl-chromen-4-one; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one
    Click to Show/Hide
Species Origin Astragalus ...     Click to Show/Hide
Astragalus
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Fabales
Family: Fabaceae
Genus: Astragalus
Disease Cervical cancer [ICD-11: 2C77] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C16H12O5
PubChem CID
5280448
Canonical SMILES
COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O
InChI
1S/C16H12O5/c1-20-14-5-2-9(6-13(14)18)12-8-21-15-7-10(17)3-4-11(15)16(12)19/h2-8,17-18H,1H3
InChIKey
ZZAJQOPSWWVMBI-UHFFFAOYSA-N
CAS Number
CAS 20575-57-9
ChEBI ID
CHEBI:17793
Herb ID
HBIN019425
SymMap ID
SMIT01316
TCMSP ID
MOL000417
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Resistance can be Reversed by This NP
          Doxorubicin      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Reversing Drug Resistance     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression SIRT1  Molecule Info 
Pathway MAP
                    In-vitro Model H9c2(2-1) CVCL_0286 Healthy Rattus norvegicus
                    In-vivo Model Male Kunming mice (8- 10 weeks old; body weight: 22 +/- 2 g) were used to construct a short-term model of cardiomyopathy.
                    Experimental
                    Result(s)
Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway.
Target and Pathway
Target(s) WD repeat-containing protein 7 (BATF2)  Molecule Info  [3]
References
Reference 1 Calycosin inhibits viability, induces apoptosis, and suppresses invasion of cervical cancer cells by upregulating tumor suppressor miR-375. Arch Biochem Biophys. 2020 Sep 30;691:108478.
Reference 2 Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway. Phytother Res. 2020 Mar;34(3):649-659.
Reference 3 Calycosin suppresses TGF-Beta-induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells. J Exp Clin Cancer Res. 2019 Jun 7;38(1):240.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China